Edgewise director granted 16,377 stock options

Edgewise Therapeutics director Jonathan C. Fox received a grant of stock options, giving him rights to acquire 16,377 shares of common stock.

Rhea-AI Filing Summary

Edgewise Therapeutics director Jonathan C. Fox received a grant of stock options, giving him rights to acquire 16,377 shares of common stock. The options have an exercise price of $35.59 per share and fully vest on the earlier of June 5, 2027 or the business day before the 2027 annual stockholder meeting. Following this grant, he holds 16,377 stock options directly as reported in this filing. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 16,377 shares

Grant/Award 1 txn

Insider Fox Jonathan C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,377	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,377 contracts (Direct)

Footnotes (1)

1. F1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Key Figures

Stock options granted: 16,377 options Exercise price: $35.59 per share Underlying shares: 16,377 shares +4 more

7 metrics

Stock options granted 16,377 options Grant reported on Form 4

Exercise price $35.59 per share Stock option exercise price

Underlying shares 16,377 shares Common stock underlying options

Options after transaction 16,377 options Total derivative holdings following grant

Grant date June 5, 2026 Stock option award date

Vesting date June 5, 2027 Latest vesting date per footnote

Expiration date June 5, 2036 Option expiration date

Key Terms

Stock Option (Right to Buy), exercise price, derivative, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 35.5900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

vesting financial

"100% of the Stock Options granted on June 5, 2026 will become vested"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholder financial

"business day prior to the 2027 annual meeting of stockholder"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edgewise Therapeutics (EWTX) director Jonathan C. Fox report in this Form 4?

Jonathan C. Fox reported receiving a grant of stock options for 16,377 shares of Edgewise Therapeutics common stock. These are compensation-related derivative awards, not open-market share purchases or sales, and are exercisable into common stock at a fixed price per share.

How many Edgewise Therapeutics (EWTX) stock options were granted to Jonathan C. Fox?

He was granted stock options covering 16,377 shares of Edgewise Therapeutics common stock. This full amount is reported as directly owned following the transaction, providing him with potential future rights to acquire the same number of common shares if the options are exercised.

What is the exercise price of Jonathan C. Fox’s Edgewise Therapeutics (EWTX) stock options?

The stock options have an exercise price of $35.59 per share. This means Fox can buy Edgewise Therapeutics common stock at $35.59 per share once the options are vested and exercisable, regardless of the market price at that future time.

When do Jonathan C. Fox’s Edgewise Therapeutics (EWTX) stock options vest?

The options vest 100% on the earlier of June 5, 2027 or the business day before Edgewise Therapeutics’ 2027 annual stockholder meeting. Full vesting on one date means all granted options become exercisable at once, rather than in installments.

Is Jonathan C. Fox’s Form 4 transaction in Edgewise Therapeutics (EWTX) a purchase or sale?

The filing shows an acquisition of stock options as a grant, coded “A” for award. It is not an open-market purchase or sale of common shares but a compensation-related derivative grant, with no reported buy or sell of stock in the market.

How is ownership of the Edgewise Therapeutics (EWTX) options held by Jonathan C. Fox classified?

The options are reported as held with direct ownership. Direct ownership means they are attributed personally to Jonathan C. Fox rather than through an intermediary entity such as a trust, partnership, or family investment vehicle, based on this Form 4 disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 06:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jonathan C

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.59	06/05/2026		A		16,377		06/02/2027(1)	06/05/2036	Common Stock	16,377	$0.00	16,377	D

Explanation of Responses:

1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)